Active Ingredient
Ceftriaxone Sodium equivalent to Ceftriaxone 500mg per vial for intravenous administration
What Oxidil IV Injection 500mg Is Used For
Oxidil IV Injection 500mg contains ceftriaxone sodium, a third-generation cephalosporin antibiotic at a higher unit dose, administered intravenously for the treatment of serious, severe, and life-threatening bacterial infections in hospitalized adults and children where high systemic antibiotic concentrations must be rapidly achieved and reliably maintained. The 500mg vial provides greater dosing flexibility for weight-based pediatric dosing, allows preparation of adult doses with fewer vials, and supports high-dose treatment protocols for severe infections. This medication is indicated for:
- Serious lower respiratory tract infections including severe community-acquired pneumonia, hospital-acquired pneumonia, ventilator-associated pneumonia, empyema, and lung abscess caused by susceptible organisms
- Bacterial meningitis and other central nervous system infections where ceftriaxone's ability to penetrate the blood-brain barrier and achieve therapeutic concentrations in cerebrospinal fluid makes it one of the most important antibiotics in clinical practice for this indication
- Serious skin and soft tissue infections including severe cellulitis, necrotizing fasciitis requiring systemic antibiotic support alongside surgical debridement, infected pressure ulcers, and serious wound infections
- Bone and joint infections including acute and chronic osteomyelitis and septic arthritis requiring prolonged parenteral antibiotic therapy to achieve adequate drug concentrations in poorly vascularized bone tissue
- Complicated urinary tract infections including complicated pyelonephritis, renal abscess, and infections associated with structural urinary tract abnormalities, obstruction, or resistant organisms where oral therapy has failed or is not feasible
- Bacterial septicemia and septic shock, where intravenous ceftriaxone forms a critical component of empirical broad-spectrum antibiotic coverage and where timely administration directly affects patient survival
- Intra-abdominal infections including severe peritonitis, cholangitis, and biliary tract infections in combination with appropriate anaerobic antimicrobial coverage
- Pelvic inflammatory disease and serious gynecological infections requiring parenteral therapy
- Febrile neutropenia in oncology patients as part of empirical broad-spectrum antibiotic coverage
- Lyme disease in patients with neurological involvement or other severe manifestations requiring parenteral treatment
- Pre-operative surgical prophylaxis before high-risk procedures including cardiac, orthopedic, abdominal, and neurosurgical procedures where parenteral antibiotic prophylaxis is indicated by current guidelines
Ceftriaxone is a bactericidal antibiotic that exerts its antibacterial effect by binding to and irreversibly inactivating penicillin-binding proteins located on the inner membrane of bacterial cell walls. This binding blocks the final transpeptidation step in the biosynthesis of peptidoglycan, the essential structural polymer that gives the bacterial cell wall its rigidity and integrity. Disruption of peptidoglycan synthesis causes progressive structural weakening of the cell wall, leading to bacterial cell lysis and death through osmotic pressure. Ceftriaxone's bactericidal mechanism distinguishes it from bacteriostatic antibiotics and is particularly important in the management of life-threatening infections including meningitis and septicemia, where rapid bacterial killing is essential for preventing irreversible organ damage and death. Ceftriaxone demonstrates clinically important broad-spectrum activity against gram-positive pathogens including Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus where methicillin sensitivity is confirmed, and against a wide range of clinically important gram-negative pathogens including Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, Neisseria meningitidis, Neisseria gonorrhoeae, Proteus mirabilis, and Serratia marcescens. Its stability against many beta-lactamase enzymes produced by gram-negative bacteria extends its activity against organisms resistant to earlier generation penicillins and cephalosporins. The exceptionally long plasma half-life of ceftriaxone, approximately 6-8 hours in adults with normal organ function, supports once or twice daily dosing, significantly simplifying administration in the inpatient setting compared to antibiotics requiring more frequent dosing intervals.
Important Safety Information
Who Should NOT Receive Oxidil IV Injection 500mg
Do not administer this medication to patients who have a documented hypersensitivity or anaphylactic reaction to ceftriaxone, any other cephalosporin antibiotic, or any excipients in the intravenous formulation, have a history of severe immediate hypersensitivity reaction including anaphylaxis to penicillin or other beta-lactam antibiotics as clinically significant cross-reactivity exists between different beta-lactam antibiotic classes, are neonates of 41 weeks corrected gestational age or younger where ceftriaxone carries specific and serious risks including fatal bilirubin encephalopathy, are hyperbilirubinemic neonates or premature infants as ceftriaxone competes with bilirubin for albumin binding sites and can cause kernicterus even at therapeutic doses, require concurrent administration of calcium-containing intravenous solutions or preparations as the combination produces insoluble ceftriaxone-calcium precipitates capable of causing fatal pulmonary and renal complications, are receiving rilpivirine or nelfinavir-based antiretroviral regimens where the omeprazole component of concurrent acid suppression therapy may confound management, or have no confirmed or strongly clinically suspected bacterial infection within ceftriaxone's spectrum of activity warranting parenteral third-generation cephalosporin therapy.
Serious Warnings and Precautions
Anaphylaxis and Severe Hypersensitivity Reactions: Serious and potentially fatal hypersensitivity reactions including anaphylactic shock, severe bronchospasm, angioedema, generalized urticaria, and life-threatening cutaneous reactions can occur with intravenous ceftriaxone administration, even in patients with no prior documented history of cephalosporin or beta-lactam allergy. The intravenous route delivers the full dose directly into systemic circulation, meaning hypersensitivity reactions develop more rapidly and can reach greater severity than with oral or intramuscular administration. A comprehensive allergy history covering all prior antibiotic exposures and reactions must be documented before the first dose. Full emergency resuscitation capability including epinephrine, intravenous antihistamines, corticosteroids, airway management equipment, oxygen, and cardiovascular support must be immediately available throughout every infusion and for an adequate observation period following completion. Any sign of hypersensitivity during infusion including new onset flushing, urticaria, periorbital or facial swelling, difficulty breathing, stridor, bronchospasm, hypotension, or loss of consciousness requires immediate cessation of the infusion and prompt initiation of emergency anaphylaxis management.
Ceftriaxone-Calcium Precipitation — Absolute Contraindication: This represents one of the most critical drug incompatibilities in intravenous therapy. Ceftriaxone must never under any circumstances be mixed with, administered simultaneously through the same intravenous line as, or infused sequentially without adequate flushing before or after any calcium-containing intravenous solution or preparation. Incompatible calcium-containing solutions include Ringer's lactate, Hartmann's solution, Ringer's acetate, and total parenteral nutrition formulations containing calcium. The chemical interaction between ceftriaxone and calcium ions forms insoluble microcrystalline precipitates that deposit in the microvasculature of the lungs and kidneys, causing pulmonary infiltrates, acute respiratory failure, and acute kidney injury. Fatal cases of this interaction have been reported and documented in the medical literature, with the most severe and consistently fatal outcomes occurring in neonates. In neonates, concurrent use of ceftriaxone with any calcium-containing preparation by any route, at any infusion site, and at any time interval between the two drugs is absolutely and unconditionally contraindicated. In adults and older children, when both ceftriaxone and calcium-containing intravenous solutions are clinically required, they must be administered through entirely separate intravenous lines placed at different anatomical sites, and if sequential administration through the same line is unavoidable, the line must be thoroughly flushed with a large volume of compatible calcium-free solution between the two medications.
Bacterial Meningitis — Clinical Urgency and Dosing Precision: Ceftriaxone is a first-line antibiotic for bacterial meningitis caused by susceptible organisms including Neisseria meningitidis and Streptococcus pneumoniae. In this indication, achieving and sustaining cerebrospinal fluid drug concentrations well above the minimum inhibitory concentration of the causative organism is essential for bacterial eradication and prevention of neurological sequelae. Higher doses at the upper end of the recommended range are required for meningitis compared to other indications, and dosing must be precisely calculated based on current clinical guidelines and the patient's weight and renal function. Antibiotic administration in suspected bacterial meningitis must not be delayed for lumbar puncture or neuroimaging if the patient is deteriorating rapidly, as each hour of delay significantly increases the risk of death and permanent neurological disability.
Bacterial Septicemia and Septic Shock: Septicemia and septic shock represent medical emergencies where the timely administration of effective antibiotics is one of the most important determinants of survival. Current international sepsis management guidelines recommend administration of appropriate intravenous antibiotics within one hour of recognition of septic shock and within three hours for other sepsis presentations. Blood cultures and other relevant microbiological specimens must be collected immediately before antibiotic administration wherever clinically feasible, but must never cause delays to antibiotic initiation in hemodynamically unstable patients. In patients with septic shock, ceftriaxone is commonly used as part of combination empirical antibiotic therapy alongside agents providing coverage for organisms outside ceftriaxone's spectrum including Pseudomonas aeruginosa and anaerobic bacteria, depending on the suspected source of infection.
Clostridium difficile-Associated Diarrhea and Pseudomembranous Colitis: Ceftriaxone, as a broad-spectrum cephalosporin, carries a particularly significant risk of precipitating Clostridium difficile infection by disrupting the normal protective gastrointestinal microbiome and allowing overgrowth of toxin-producing Clostridium difficile strains. The clinical spectrum ranges from mild, self-limiting diarrhea to severe and life-threatening pseudomembranous colitis with toxic megacolon, colonic perforation, systemic sepsis, and death. This complication can manifest during antibiotic treatment or weeks to months after completion. Any new onset diarrhea in a patient receiving or who has recently completed ceftriaxone therapy must prompt immediate clinical evaluation and testing for Clostridium difficile toxin. Antiperistaltic medications including loperamide are contraindicated in suspected Clostridium difficile colitis as they impair toxin clearance and can precipitate toxic megacolon.
Surgical Prophylaxis — Timing and Single Dose Principle: When used for preoperative surgical prophylaxis, the single dose of ceftriaxone must be administered within the 30-90 minute window before surgical incision to ensure adequate tissue concentrations are present at the time of maximum contamination risk. Prophylactic antibiotic administration outside this window, whether too early or too late relative to incision, significantly reduces its effectiveness. Current evidence does not support the use of prolonged postoperative antibiotic prophylaxis beyond a single preoperative dose for most surgical procedures, and such use increases the risk of Clostridium difficile infection, antibiotic resistance, and adverse effects without providing additional infection prevention benefit.
Hemolytic Anemia: Severe and fatal immune-mediated hemolytic anemia has been documented with ceftriaxone therapy, most commonly in children but also reported in adults. This serious adverse effect can develop during treatment or shortly after its completion. Unexplained pallor, progressive fatigue and weakness, new onset jaundice, dark or cola-colored urine, or a significant unexplained decrease in hemoglobin or hematocrit during or following ceftriaxone therapy must prompt immediate investigation for immune hemolytic anemia including direct antiglobulin test. Ceftriaxone must be stopped immediately upon clinical suspicion of hemolytic anemia, as continued administration in the presence of this condition can be fatal.
Biliary Complications: High biliary excretion of ceftriaxone can result in formation of calcium-ceftriaxone precipitates within the gallbladder, producing biliary sludge and pseudolithiasis that may present with symptoms indistinguishable from true cholelithiasis including right upper quadrant pain, nausea, vomiting, and biliary colic. This complication is more common with higher doses and longer treatment durations and in patients receiving concurrent total parenteral nutrition. Ultrasound examination of the gallbladder is indicated in patients developing biliary symptoms during treatment. The precipitates are typically reversible and resolve after stopping ceftriaxone, usually within weeks.
Seizures and Neurotoxicity: Encephalopathy, asterixis, neuromuscular excitability, myoclonus, and seizures have been reported in patients receiving ceftriaxone, most commonly in those with renal impairment where inadequate dose adjustment leads to drug accumulation and central nervous system toxicity. Patients with pre-existing seizure disorders, renal impairment, or other risk factors for neurotoxicity should be monitored carefully for neurological changes during therapy.
Superinfection and Antimicrobial Resistance: Prolonged high-dose intravenous ceftriaxone suppresses susceptible components of the normal microbiome and selects for resistant organisms including extended-spectrum beta-lactamase-producing Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter species, Enterococcus species, and Candida species. Unexpected clinical deterioration, new fever, or microbiological evidence of a new pathogen during therapy must trigger immediate reassessment of the antibiotic regimen and consideration of broader or alternative coverage.
Notify the attending medical team and initiate emergency management immediately if the patient develops any sign of anaphylaxis during or following infusion, shows evidence of severe hemolytic anemia, develops signs of Clostridium difficile colitis, experiences biliary pain during treatment, shows neurological deterioration including new onset seizures or confusion, develops unexpected clinical deterioration or signs of a superinfection, shows evidence of significant coagulopathy, or any other unexpected or concerning clinical change occurs during the course of treatment.
Consult Senior Medical Staff or Clinical Pharmacist Before Use In Patients Who Have:
A documented history of allergy to any cephalosporin, penicillin, or other beta-lactam antibiotic, renal impairment of any severity requiring dose adjustment particularly in patients with combined renal and hepatic impairment where accumulation risk is greatest, hepatic impairment where reduced drug metabolism and biliary excretion may alter pharmacokinetics, a history of gastrointestinal disease particularly inflammatory bowel disease or prior Clostridium difficile infection, biliary tract disease or gallbladder abnormalities predisposing to ceftriaxone-related biliary complications, a history of seizure disorders or epilepsy, are neonates or premature infants where use carries specific and serious risks requiring specialist oversight and is generally avoided, are pregnant or breastfeeding where benefit-risk assessment must be carefully documented, have pre-existing coagulopathy or are receiving anticoagulant therapy requiring more frequent monitoring, are malnourished or have documented or suspected vitamin K deficiency, are receiving concurrent nephrotoxic or ototoxic medications, have febrile neutropenia or other immunocompromised states where combination antibiotic regimens may be required, are receiving complex intravenous therapy through shared lines where compatibility must be verified, or are critically ill patients with multiple organ dysfunction where altered pharmacokinetics affect drug levels and dosing requirements.
Common Side Effects
When correctly prepared and administered by slow intravenous infusion, Oxidil IV Injection 500mg is generally well-tolerated in most patients. However, infusion site reactions including pain, erythema, swelling, and thrombophlebitis at the intravenous site are commonly reported. Other frequently observed adverse effects include diarrhea and loose stools, nausea and vomiting, abdominal discomfort, headache, elevated liver enzymes and bilirubin on biochemical testing, elevated serum creatinine and blood urea, skin rash and urticaria, eosinophilia on blood count examination, prolonged prothrombin time, and in patients receiving prolonged courses, secondary candidal superinfection of the oral mucosa or genitourinary tract.
Serious adverse effects requiring immediate clinical escalation and intervention include anaphylaxis and severe systemic hypersensitivity reactions, severe cutaneous adverse reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis, severe immune hemolytic anemia including fatal cases, Clostridium difficile pseudomembranous colitis with or without toxic megacolon, ceftriaxone-calcium precipitation causing pulmonary infiltrates or renal failure, symptomatic biliary pseudolithiasis requiring clinical management, seizures and encephalopathy particularly in patients with renal impairment, clinically significant coagulopathy and hemorrhage, severe hematological toxicity including thrombocytopenia and neutropenia, and superinfection with multidrug-resistant organisms or invasive fungal pathogens.
Drug Interactions
A thorough and documented medication reconciliation is mandatory before initiating Oxidil IV Injection 500mg in any patient, particularly those in the inpatient and critical care setting where polypharmacy is common. At the higher 500mg vial dose and the total daily doses used in severe infections, some interactions may be more clinically significant than at lower doses. Key interactions include those with calcium-containing intravenous solutions where concurrent use is absolutely contraindicated, warfarin and other anticoagulants where ceftriaxone potentiates anticoagulant effect through intestinal vitamin K suppression requiring significantly more frequent INR monitoring and likely dose adjustment throughout treatment and following its completion, aminoglycoside antibiotics including gentamicin, amikacin, and tobramycin commonly co-prescribed in serious infections where the combination carries additive nephrotoxicity and ototoxicity risk and the two agents must never be admixed in the same infusion bag or syringe, loop diuretics including furosemide frequently used in critically ill patients where concurrent administration increases nephrotoxicity risk and requires careful renal function monitoring, other nephrotoxic agents including vancomycin, amphotericin B, ciclosporin, and contrast media where concurrent use demands vigilant renal function monitoring, live bacterial vaccines including oral typhoid vaccine where concurrent systemic antibiotic therapy impairs vaccine immunogenicity and concurrent administration should be deferred, oral hormonal contraceptives where broad-spectrum antibiotic therapy may reduce contraceptive effectiveness through disruption of enterohepatic cycling and patients should be counseled on the use of additional contraceptive precautions during and immediately after antibiotic treatment, probenecid which affects renal clearance of beta-lactam antibiotics, and any other medications being co-administered through shared intravenous access where physical and chemical compatibility must be verified by a pharmacist before co-administration.
How Oxidil IV Injection 500mg Is Administered
Oxidil IV Injection must only be prepared and administered by or under the direct supervision of appropriately trained healthcare professionals following established institutional protocols, aseptic preparation guidelines, and the manufacturer's specific preparation and administration instructions. Self-administration outside of a supervised clinical setting is not appropriate for this medication.
Reconstitution and Dilution: Reconstitute the 500mg vial with the appropriate volume of compatible diluent as specified in the manufacturer's instructions for intravenous use. Compatible diluents include sodium chloride 0.9%, glucose 5%, and glucose 10% solutions. Never reconstitute or dilute with Ringer's lactate, Hartmann's solution, or any other calcium-containing solution. Following initial reconstitution, the solution should be further diluted in the recommended volume of compatible infusion fluid according to the manufacturer's guidance and institutional pharmacy protocols. Inspect the reconstituted and diluted solution carefully for visible particulate matter, cloudiness, and discoloration before administration. Use only clear solutions of appropriate color without visible particles.
Standard Adult Dosing: For most serious infections in adults, the recommended dose ranges from 1-4g per day administered as a once daily dose or in two equally divided doses every 12 hours depending on the severity and type of infection. For bacterial meningitis, doses of 2-4g daily are typically employed. For septicemia, doses at the upper end of the recommended range are generally used. For surgical prophylaxis, a single dose of 1-2g is administered 30-90 minutes before surgical incision. For bone and joint infections requiring prolonged therapy, doses must be individually determined based on the infecting organism, its sensitivity profile, and the patient's pharmacokinetic parameters. All dosing decisions must be confirmed by the prescribing physician or clinical pharmacist based on the specific indication, infection severity, local resistance patterns, patient weight, renal and hepatic function, and current institutional and national clinical guidelines.
Pediatric Dosing: In children beyond the neonatal period, ceftriaxone dosing is calculated based on body weight at 50-100mg per kilogram per day in one or two divided doses depending on the indication and severity of infection. For bacterial meningitis in children, doses of 100mg per kilogram per day up to a maximum of 4g daily are recommended in most current guidelines. All pediatric doses must be verified by the prescribing physician or clinical pharmacist before administration and must not exceed the recommended maximum daily dose for the specific indication. Use of ceftriaxone in neonates requires specialist infectious disease or neonatology consultation given the specific and serious risks in this age group.
Administration Technique: Administer the diluted ceftriaxone solution by slow intravenous infusion over a minimum of 30 minutes in adults and over a minimum of 60 minutes in children and patients with renal impairment where slower infusion reduces peak plasma concentrations and the associated risk of adverse effects. Never administer ceftriaxone as a rapid intravenous bolus injection, as this can cause cardiovascular adverse effects and significantly increases the risk of infusion-related reactions. The intravenous line must be flushed thoroughly with an appropriate volume of compatible calcium-free solution both before and after the ceftriaxone infusion to prevent chemical incompatibility with other medications being administered through the same line. Do not admix ceftriaxone with other antibiotics, medications, or solutions in the same infusion bag or syringe unless specific compatibility data confirming physical and chemical stability are available.
Duration of Treatment: The appropriate duration of ceftriaxone therapy is determined by the type, anatomical site, and severity of infection, the identity and antibiotic susceptibility of the causative organism where microbiological data are available, and the patient's clinical and laboratory response to treatment. Typical treatment durations include 5-7 days for uncomplicated pneumonia in responding patients, 7-14 days for septicemia, 10-21 days for bacterial meningitis depending on the causative organism, a minimum of 4-6 weeks for osteomyelitis of which the intravenous phase may be followed by appropriate oral step-down therapy, and 14 days or longer for complicated urinary tract infections with renal involvement. The treating physician must review the ongoing need for intravenous therapy at regular intervals and transition to appropriate oral antibiotic therapy as soon as the patient's clinical status permits, in accordance with antibiotic stewardship principles.
Based on our pharmacists' clinical observations, the highest-risk periods for adverse events during Oxidil IV Injection 500mg therapy are the first infusion, when hypersensitivity reactions are most likely to manifest and when clinical staff must be most vigilant, and during prolonged high-dose courses when risks of Clostridium difficile infection, hemolytic anemia, biliary complications, and superinfection accumulate progressively. Systematic daily review of the ongoing clinical justification for intravenous ceftriaxone, including assessment of microbiological results, clinical response indicators, and suitability for oral step-down therapy, is one of the most impactful antibiotic stewardship interventions available in the inpatient setting and should be a standard component of daily ward rounds and clinical pharmacy review.
What Healthcare Providers and Patients Need to Know
Antibiotic Stewardship and Resistance Prevention: Ceftriaxone is a critically important antibiotic in the management of severe bacterial infections and its continued clinical effectiveness depends on disciplined stewardship. Every prescription should be reviewed against the criteria of correct indication, correct dose, correct duration, and narrowest effective spectrum. De-escalation from empirical broad-spectrum coverage to targeted therapy based on culture and sensitivity results is a clinical and ethical obligation and should occur as a default practice whenever microbiological data support it. Extended-spectrum beta-lactamase-producing Enterobacteriaceae and other resistant organisms selected by broad-spectrum cephalosporin use represent a growing and serious threat to the management of community and hospital-acquired infections globally.
Microbiological Culture Before Treatment: Appropriate clinical specimens for culture and sensitivity testing must be collected before the first dose of ceftriaxone wherever the patient's condition allows. For septicemia, a minimum of two sets of blood cultures from different sites before the first antibiotic dose is recommended by international guidelines. For meningitis, cerebrospinal fluid must be obtained before antibiotics where lumbar puncture can be performed safely and without causing clinically unacceptable delay to treatment. For pneumonia, sputum, bronchoalveolar lavage, or blood cultures provide microbiological guidance. Pre-treatment cultures are the foundation of rational antibiotic de-escalation and are essential for identifying resistant organisms, polymicrobial infections, and pathogens outside ceftriaxone's spectrum that require additional or alternative antibiotic coverage.
Management of Bone and Joint Infections: Osteomyelitis and septic arthritis are among the most challenging bacterial infections to treat due to the poor vascularity of bone and the difficulty of achieving sustained therapeutic antibiotic concentrations in infected osseous tissue. Ceftriaxone's once-daily dosing, broad spectrum, and proven bone penetration make it a valuable option for the parenteral phase of treatment. However, adequate surgical management including joint drainage, debridement, and removal of infected or necrotic tissue is frequently required alongside antibiotic therapy for optimal outcomes. The decision to transition from intravenous to oral antibiotic therapy for bone and joint infections should be guided by clinical response, normalization of inflammatory markers, and microbiological clearance, and must be based on the availability of an oral antibiotic with demonstrated activity against the causative organism and adequate oral bioavailability.
Pregnancy and Breastfeeding: Ceftriaxone crosses the placental barrier and is present in fetal circulation and in breast milk. While available clinical data do not suggest significant teratogenicity, ceftriaxone should be used during pregnancy only when serious bacterial infection makes treatment clearly necessary and when no safer alternative antibiotic provides equivalent coverage. The decision to use ceftriaxone during pregnancy requires involvement of the treating obstetrician and careful documentation of the benefit-risk assessment. Breastfeeding women receiving ceftriaxone should discuss the implications with their healthcare provider, as while only small amounts are excreted in breast milk, the potential for disruption of the infant's gastrointestinal microbiome and development of antibiotic resistance in colonizing bacteria exists even with this low-level exposure.
Storage and Handling Instructions
Store unreconstituted vials at room temperature below 25°C, protected from direct light and moisture. Keep vials in their original packaging until immediately before preparation to preserve integrity of the lyophilized powder. Reconstituted and diluted solutions must be prepared in a designated clean area using strict aseptic technique and used within the stability period specified in the manufacturer's product information, noting that stability varies significantly based on the diluent used, the concentration of the final solution, and the storage temperature. Do not use vials showing any signs of physical damage, compromised seal integrity, abnormal discoloration of the powder or reconstituted solution, cloudiness, or visible particulate contamination. Dispose of all unused reconstituted solution, empty vials, administration sets, and sharps in strict accordance with institutional infection control policies, clinical waste segregation requirements, and applicable hazardous waste disposal regulations. Keep all vials out of reach of children at all times.
Manufacturer Information
[Manufacturer name and details would be inserted here based on your specific product]
Regulatory Status: Oxidil IV Injection 500mg is a prescription-only medication for intravenous administration exclusively in clinical settings by or under the direct supervision of trained healthcare professionals. It is not available for self-administration or unsupervised home use.
Medical Review Notice: This product information should be reviewed by a licensed physician or clinical pharmacist with expertise in infectious disease, antimicrobial therapy, and intravenous drug administration to ensure accuracy and compliance with current clinical guidelines, local and national antimicrobial resistance surveillance data, and institutional antibiotic stewardship program requirements. All prescribing decisions should be guided by current evidence-based guidelines for the specific indication, informed by available microbiological data, and subject to regular review throughout the course of treatment.
Last Updated: [Date would be inserted here]